--- title: "在美國以美國存託憑證形式交易的歐洲股票在週五的交易中小幅上漲" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/276465384.md" description: "在美國交易的歐洲股票略有上漲，標準普爾歐洲精選 ADR 指數上漲 0.1%，達到 1,845.20，周漲幅為 1.76%。值得注意的漲幅股票包括 Sequans Communications 和 DBV Technologies，而 Ascendis Pharma 和 Materialise 則在下跌之列。在英國和愛爾蘭，帝亞吉歐和 Endava 領漲，而 Biodexa Pharmaceuticals 和 Trinity Biotech 則經歷了顯著下跌。MT Newswires 不提供投資建議" datetime: "2026-02-20T16:11:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276465384.md) - [en](https://longbridge.com/en/news/276465384.md) - [zh-HK](https://longbridge.com/zh-HK/news/276465384.md) --- # 在美國以美國存託憑證形式交易的歐洲股票在週五的交易中小幅上漲 11:11 AM EST, 02/20/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts edged up 0.1% to 1,845.20 on the S&P Europe Select ADR Index late Friday morning. It was up 1.76% for the week. From continental Europe, the gainers were led by semiconductor firm Sequans Communications ( SQNS ) and biopharmaceutical company DBV Technologies ( DBVT ) , which rose 2.4% and 2% respectively. They were followed by lender ING (ING) and software firm SAP (SAP), which rose 1.7% and 1.5% respectively. The decliners from continental Europe were led by Ascendis Pharma ( ASND ) and 3D printer company Materialise (MTLS), which fell 2.8% and 2.5% respectively. They were followed by pharmaceutical firm Novo Nordisk ( NVO ) , which was down 2.4%. From the UK and Ireland, the gainers were led by alcoholic beverage company Diageo ( DEO ) and Endava ( DAVA ) , which advanced 3.6% and 3.4% respectively. They were followed by biopharmaceutical companies Akari Therapeutics ( AKTX ) and NuCana ( NCNA ) , which were up 3.1% and 2.1% respectively. The decliners from the UK and Ireland were led by Biodexa Pharmaceuticals ( BDRX ) and Trinity Biotech ( TRIB ) , which dropped 7% and 3.1% respectively. They were followed by Bicycle Therapeutics ( BCYC ) , which lost 2%. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited. ### 相關股票 - [SQNS.US](https://longbridge.com/zh-HK/quote/SQNS.US.md) - [DAVA.US](https://longbridge.com/zh-HK/quote/DAVA.US.md) - [DEO.US](https://longbridge.com/zh-HK/quote/DEO.US.md) - [DBVT.US](https://longbridge.com/zh-HK/quote/DBVT.US.md) - [SPEU.US](https://longbridge.com/zh-HK/quote/SPEU.US.md) - [TRIB.US](https://longbridge.com/zh-HK/quote/TRIB.US.md) - [BDRX.US](https://longbridge.com/zh-HK/quote/BDRX.US.md) - [ASND.US](https://longbridge.com/zh-HK/quote/ASND.US.md) - [MTLS.US](https://longbridge.com/zh-HK/quote/MTLS.US.md) ## 相關資訊與研究 - [SEAGRAM'S 7 CROWN 調和威士忌推出新的蘋果派口味，提升夏季的風味 | DEO 股票新聞](https://longbridge.com/zh-HK/news/286422217.md) - [英國Endava第三季度營收因需求疲軟下滑8.4%，錄得商譽減值](https://longbridge.com/zh-HK/news/287210665.md) - [鉅亨速報 - Factset 最新調查：Ascendis Pharma A/S - ADR(ASND-US) EPS 預估上修至 13.67 元，預估目標價為 250.22 元](https://longbridge.com/zh-HK/news/286911202.md) - [鉅亨速報 - Factset 最新調查：Ascendis Pharma A/S - ADR(ASND-US) EPS 預估上修至 13.45 元，預估目標價為 249.35 元](https://longbridge.com/zh-HK/news/286592883.md) - [鉅亨速報 - Factset 最新調查：Ascendis Pharma A/S - ADR(ASND-US) EPS 預估下修至 3.62 元，預估目標價為 252.56 元](https://longbridge.com/zh-HK/news/285610838.md)